Synlogic Stock Forecast, Price & News

Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYBX stock has increased by 62.3% and is now trading at $2.50.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Synlogic or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Synlogic a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Synlogic wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Synlogic.

Synlogic, Inc. (NASDAQ:SYBX) posted its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.47) by $0.11. Synlogic had a negative return on equity of 38.34% and a negative net margin of 2,761.83%.
View Synlogic's earnings history.

Synlogic shares reverse split before market open on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

3 equities research analysts have issued 12-month price targets for Synlogic's stock. Their forecasts range from $5.00 to $13.00. On average, they anticipate Synlogic's share price to reach $9.00 in the next year. This suggests a possible upside of 260.0% from the stock's current price.
View analysts' price targets for Synlogic.

Synlogic saw a increase in short interest in October. As of October 30th, there was short interest totaling 393,600 shares, an increase of 49.1% from the October 15th total of 264,000 shares. Based on an average daily volume of 166,300 shares, the days-to-cover ratio is currently 2.4 days. Approximately 1.9% of the company's stock are sold short.
View Synlogic's Short Interest.

Some companies that are related to Synlogic include Altimmune (ALT), Calithera Biosciences (CALA), CytomX Therapeutics (CTMX), BeyondSpring (BYSI), MEI Pharma (MEIP), Magenta Therapeutics (MGTA), Verastem (VSTM), Orphazyme A/S (ORPH), Larimar Therapeutics (LRMR), RedHill Biopharma (RDHL), Fulcrum Therapeutics (FULC), Osmotica Pharmaceuticals (OSMT), iBio (IBIO), OrganiGram (OGI) and Axovant Sciences (AXON).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Synlogic's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Jane Street Group LLC (0.07%), Acadian Asset Management LLC (0.06%), Bank Julius Baer & Co. Ltd Zurich (0.06%) and Morgan Stanley (0.05%). Company insiders that own Synlogic stock include Paul Francis Miller and Richard P Shea.
View institutional ownership trends for Synlogic.

SYBX stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, and Morgan Stanley.
View insider buying and selling activity for Synlogic.

SYBX stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, and Bank Julius Baer & Co. Ltd Zurich.
View insider buying and selling activity for Synlogic.

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYBX stock can currently be purchased for approximately $2.50.

Synlogic has a market capitalization of $87.09 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Synlogic employs 76 workers across the globe.

The official website for Synlogic is www.synlogictx.com.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]